31,774 results match your criteria allograft rejection


A Multifaceted Medication Adherence Promotion System to Reduce Late Kidney Allograft Rejection in Children and Young Adults.

Am J Kidney Dis 2022 Jan 11. Epub 2022 Jan 11.

Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Division of Transplantation, Department of Surgery, Northwestern Medicine, Chicago, Illinois. Electronic address:

View Article and Full-Text PDF
January 2022

Long-term outcomes after heart transplantation using ex-vivo allograft perfusion in standard risk donors: A single center experience.

Clin Transplant 2022 Jan 14:e14591. Epub 2022 Jan 14.

Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Introduction: The Organ Care System (OCS) is an ex-vivo perfusion platform for donor heart preservation. Short/mid-term post-transplant outcomes after its use are comparable to standard cold storage (CS). We evaluated long-term outcomes following its use. Read More

View Article and Full-Text PDF
January 2022

Graft fibrosis over 10 to 15 years in pediatric liver transplant recipients: Multi-center study of paired, longitudinal surveillance biopsies.

Liver Transpl 2022 Jan 13. Epub 2022 Jan 13.

Department of Surgery, University of California San Francisco, San Francisco, CA, USA.

Background: Previous single-center, cross-sectional studies have reported a steep increase in the prevalence and severity of fibrosis through 10-15 years after pediatric liver transplantation. We report a multi-center study of paired surveillance biopsies in a contemporary cohort.

Methods: Children who underwent liver transplant at <6 years old and had paired surveillance liver biopsies were enrolled (n=78, 35% female, median 1. Read More

View Article and Full-Text PDF
January 2022

Cytosporone B (Csn-B), an NR4A1 agonist, attenuates acute cardiac allograft rejection by inducing differential apoptosis of CD4+T cells.

Int Immunopharmacol 2022 Jan 10;104:108521. Epub 2022 Jan 10.

Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address:

CD4+T cell-mediated acute rejection remains a major factor that affects the early survival of transplanted organs post-transplantation. Here, we reveal that nuclear receptor subfamily 4 Group A member 1 (Nr4A1) was upregulated during cardiac allograft rejection and that the increased Nr4A1 was primarily localized in intragraft-infiltrating CD4+T cells. Nr4A1 acts as a transcription factor with an important role in CD4+T cell apoptosis, differentiation and T cell dysfunction, which indicates that Nr4A1 may play a critical role in transplant rejection. Read More

View Article and Full-Text PDF
January 2022

Biological Variation of Donor-Derived Cell-Free DNA in Stable Lung Transplant Recipients.

J Appl Lab Med 2022 Jan 12. Epub 2022 Jan 12.

Laboratory of Applied Precision Omics (APO) and Genomic Research Alliance for Transplantation (GRAfT), National Institutes of Health, Bethesda, MD, USA.

Background: Prior studies demonstrate that donor-derived cell-free DNA (dd-cfDNA) in lung transplant recipients may serve as a marker of allograft injury for detecting allograft rejection and infection. Clinical interpretation of dd-cfDNA requires understanding its biological variation in stable lung transplant patients in order to identify abnormal results suggesting underlying allograft dysfunction. This study establishes the biological variation and reference change values (RCV) of dd-cfDNA in stable lung transplant recipients using an analytically validated assay with an established analytic coefficient of variation (CVA). Read More

View Article and Full-Text PDF
January 2022

Reconstruction of the trachea and carina: Surgical reconstruction, autologous tissue transplantation, allograft transplantation, and bioengineering.

Thorac Cancer 2022 Jan 13. Epub 2022 Jan 13.

Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.

There have been significant advancements in medical techniques in the present epoch, with the emergence of some novel operative substitutes. However, the treatment of tracheal defects still faces tremendous challenges and there is, as yet, no consensus on tracheal and carinal reconstruction. In addition, surgical outcomes vary in different individuals, which results in an ambiguous future for tracheal surgery. Read More

View Article and Full-Text PDF
January 2022

RtNet: a deep hybrid neural networks for the identification of acute rejection and chronic allograft nephropathy after renal transplantation using multiparametric MRI.

Nephrol Dial Transplant 2022 Jan 10. Epub 2022 Jan 10.

Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.

Background: Reliable diagnosis of the cause of renal allograft dysfunction is of clinical importance. The aim of this study is to develop a hybrid deep learning approach for determining acute rejection (AR), chronic allograft nephropathy (CAN) and renal function in kidney-allografted patients by multimodality integration.

Methods: Clinical and MRI data of 252 kidney-allografted patients who underwent post-transplantation MRI between Dec 2014 and Nov 2019 were retrospectively collected. Read More

View Article and Full-Text PDF
January 2022

International Survey of Clinical Monitoring Practices in Pancreas and Islet Transplantation.

Transplantation 2022 Jan 10. Epub 2022 Jan 10.

Division of Transplantation, Department of Surgery, University of California, San Francisco, San Francisco, CA. Department of Surgery, Multi-Organ Transplant Program, Toronto General Hospital, Toronto, ON. Division of Transplantation, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, and Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. Division of Transplantation and Visceral Surgery, Department of Surgery, Geneva University Hospital, Geneva, Switzerland. Division of Transplantation, Department of Surgery, and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL. Department of Medicine, St. Vincent's Hospital, St. Vincent's Institute of Medical Research, University of Melbourne, Melbourne, Victoria, Australia. Department of Transplantation, Nephrology and Clinical Immunology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France. Department of Kidney Pancreas Transplantation, Instituto de Trasplantes y Alta Complejidad (ITAC - Nephrology), Buenos Aires, Argentina. Department of Medicine, Leiden University Medical Center, Leiden, Netherlands. Department of General, Visceral and Transplant Surgery, University Hospital Grosshadern, Ludwig Maximilian's University, Munich, Germany. Department of Transplant Medicine and Institute for Surgical Research, Oslo University Hospital, Oslo, Norway. Department of General Surgery, Wake Forest School of Medicine, Winston-Salem, NC.

Background: The long-term outcomes of both pancreas and islet allotransplantation have been compromised by difficulties in the detection of early graft dysfunction at a time when a clinical intervention can prevent further deterioration and preserve allograft function. The lack of standardized strategies for monitoring pancreas and islet allograft function prompted an international survey established by an International Pancreas and Islet Transplant Association/European Pancreas and Islet Transplant Association working group.

Methods: A global survey was administered to 24 pancreas and 18 islet programs using Redcap. Read More

View Article and Full-Text PDF
January 2022

Split-Combine Click-SELEX Reveals Ligands Recognizing the Transplant Rejection Biomarker CXCL9.

ACS Chem Biol 2022 Jan 12. Epub 2022 Jan 12.

Chemical Biology & Chemical Genetics, Life and Medical Sciences (LIMES) Institute, University of Bonn, Gerhard-Domagk-Str. 1, Bonn 53121, Germany.

Renal rejection is a major incidence in patients after kidney transplantation and associated with allograft scarring and function loss, especially in antibody-mediated rejection. Regular clinical monitoring of kidney-transplanted patients is thus necessary, but measuring donor-specific antibodies is not always predictive, and graft biopsies are time-consuming and costly and may come up with a histological result unsuspicious for rejection. Therefore, a noninvasive diagnostic approach to estimate an increased probability of kidney graft rejection by measuring specific biomarkers is highly desired. Read More

View Article and Full-Text PDF
January 2022

Outcomes of diabetic patients with end-stage heart failure listed for heart transplantation: A propensity-matched analysis.

Clin Transplant 2022 Jan 12:e14590. Epub 2022 Jan 12.

Division of Heart Failure and Transplant, University of Iowa Hospitals and Clinics, Iowa, IA, United States.

Background: We investigated the current trends and outcomes of diabetic patients listed for heart transplants in the U.S. and provided a method for risk-stratification. Read More

View Article and Full-Text PDF
January 2022

miR-31, miR-155, and miR-221 expression profiles and their association with graft skin tolerance in a syngeneic vs. allogeneic murine skin transplantation model.

J Burn Care Res 2022 Jan 9. Epub 2022 Jan 9.

Laboratory of Connective Tissue, Centro Nacional de Investigación y Atención a Quemados, Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico.

Grafting is the gold standard for the treatment of severe skin burns. Frequently, allogeneic tissue is the only transient option for wound coverage, but their use risks damage to surrounding tissues. MicroRNAs have been associated with acute rejection of different tissues/organs. Read More

View Article and Full-Text PDF
January 2022

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of Kidney Transplant Recipients.

Ann Transplant 2022 Jan 12;27:e934738. Epub 2022 Jan 12.

Department of Medical Sciences, Section of Infectious Diseases, Uppsala University, Uppsala, Sweden.

BACKGROUND BK virus (BKV) infection after kidney transplantation leads to BKV-associated nephropathy (BKVAN) in up to 10% of recipients, and is associated with an increased risk of allograft dysfunction or loss. The objective of this study was to estimate the incidence of BKVAN and to analyze whether enhanced induction is associated with an increased risk of BKVAN, possibly justifying more intensive surveillance. MATERIAL AND METHODS This was a single-center retrospective cohort study. Read More

View Article and Full-Text PDF
January 2022

'Snapshot' of an annual data from a large South Indian Renal Biopsy Registry.

Saudi J Kidney Dis Transpl 2021 Mar-Apr;32(2):522-529

Renopath, Center for Renal and Urological Pathology, Chennai, India.

Results from biopsy registries are important to know about the prevalence of renal diseases. In large studies done over several years, significant interobserver variability could have existed. Single-year biopsy registry data are analyzed in this study. Read More

View Article and Full-Text PDF
January 2022

Posttransplant lymphoproliferative disorder in renal transplant recipients: Experience from a Tertiary Care Center.

Saudi J Kidney Dis Transpl 2021 Mar-Apr;32(2):418-427

Department of Laboratory Science and Molecular Medicine, Army Hospital (Research and Referral), New Delhi, India.

Posttransplant lymphoproliferative disorders (PTLDs) are potentially fatal complications arising after solid organ or hematopoietic stem cell transplant. The most crucial factor in pathogenesis of PTLDs is either a primary infection with Epstein-Barr virus or reactivation of its latent state due to immune dysregulation. This complex pathobiology leads to a myriad of clinical manifestations due to uncontrolled lymphoproliferation that may be reactive, polymorphous or monomorphous. Read More

View Article and Full-Text PDF
January 2022

Tacrolimus intrapatient variability in BK virus nephropathy and chronic calcineurin toxicity in kidney transplantation.

Saudi J Kidney Dis Transpl 2021 Mar-Apr;32(2):348-354

Department of General Surgery, Division of Transplantation, Baskent University Ankara Hospital, Ankara, Turkey.

Intrapatient variability (IPV) in tacrolimus has been increasingly acknowledged as a risk factor for poor graft survival after kidney transplantation. Although past studies have mainly accounted for IPV in acute or chronic rejection states as due to underimmunosuppression, this is not yet clear. So far, tacrolimus IPV for BK virus-associated nephropathy (BKVN) and chronic calcineurin inhibitor toxicity (CNIT) has not been investigated. Read More

View Article and Full-Text PDF
January 2022

Macrophages in transplant rejection.

Authors:
Shaochen Yu Jian Lu

Transpl Immunol 2022 Jan 10;71:101536. Epub 2022 Jan 10.

Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, No. 218, Jixi Road, Shushan District, Hefei, Anhui 230022, China. Electronic address:

Transplant rejection is one of the primary factors leading to loss of allograft function, and macrophages are involved in allograft rejection. Macrophages polarize into different phenotypes according to stimulation by different external factors. Different types of macrophages play distinct roles in inflammation, tumors, and autoimmune diseases and are involved in transplant rejection. Read More

View Article and Full-Text PDF
January 2022

Higher levels of allograft injury in black patients early after heart transplantation.

J Heart Lung Transplant 2021 Dec 23. Epub 2021 Dec 23.

Genomic Research Alliance for Transplantation (GRAfT), Bethesda, Maryland; Laborarory of Applied Precision Omics (APO), Division of Intramural Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland; Department of Medicine, Stanford University School of Medicine, Palo Alto, California. Electronic address:

Black patients suffer higher rates of antibody-mediated rejection and have worse long-term graft survival after heart transplantation. Donor-derived cell free DNA (ddcfDNA) is released into the blood following allograft injury. This study analyzed %ddcfDNA in 63 heart transplant recipients categorized by Black and non-Black race, during the first 200 days after transplant. Read More

View Article and Full-Text PDF
December 2021

Islet transplantation into brown adipose tissue can delay immune rejection.

JCI Insight 2022 Jan 11. Epub 2022 Jan 11.

Department of Microbiology, University of Alabama at Birmingham, Birmingham, United States of America.

Type 1 diabetes is an autoimmune disease characterized by insulin-producing beta-cell destruction. While islet transplantation restores euglycemia and improves patient outcomes, an ideal transplant site remains elusive. Brown adipose tissue (BAT) is a highly vascularized and anti-inflammatory microenvironment. Read More

View Article and Full-Text PDF
January 2022

Fatal Allograft Rejection and Cardiac Allograft Vasculopathy After Treatment With Pembrolizumab for Metastatic Melanoma in a Heart Transplant Recipient: A Case Report.

Transplant Proc 2022 Jan 7. Epub 2022 Jan 7.

Moffitt Cancer Center, Tampa, Florida.

Checkpoint inhibitors decrease the progression of many cancers. However, the experience in immunosuppressed patients is limited, with reports of possible serious adverse events. We present a heart transplant recipient treated with pembrolizumab for metastatic melanoma who developed fatal rejection. Read More

View Article and Full-Text PDF
January 2022

Poor Long-Term Renal Allograft Survival in Patients with Chronic Antibody-Mediated Rejection, Irrespective of Treatment-A Single Center Retrospective Study.

J Clin Med 2021 Dec 30;11(1). Epub 2021 Dec 30.

Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, 10117 Berlin, Germany.

The Banff 2017 report permits the diagnosis of pure chronic antibody-mediated rejection (cAMR) in absence of microcirculation inflammation. We retrospectively investigated renal allograft function and long-term outcomes of 67 patients with cAMR, and compared patients who received antihumoral therapy (cAMR-AHT, = 21) with patients without treatment (cAMRwo, = 46). At baseline, the cAMR-AHT group had more concomitant T-cell-mediated rejection (9/46 (19. Read More

View Article and Full-Text PDF
December 2021

Low dose rabbit antithymocyte globulin is non-inferior to higher dose in low-risk pediatric kidney transplant recipients.

Pediatr Nephrol 2022 Jan 10. Epub 2022 Jan 10.

Division of Nephrology, Department of Pediatrics, Stanford University, Palo Alto, CA, USA.

Background: Currently, there is no consensus among pediatric kidney transplant centers regarding the use and regimen for immunosuppressive induction therapy.

Methods: In this single center, retrospective cohort study, pediatric kidney transplant recipients transplanted between 1 May 2013 and 1 May 2018 with rabbit antithymocyte globulin (rATG) induction were included. We stratified patients based on immunological risk, with high risk defined as those with repeat transplant, preformed donor specific antibody, current panel-reactive antibodies > 20%, 0 antigen match and/or African-American heritage. Read More

View Article and Full-Text PDF
January 2022

Anti-C4d chimeric antigen receptor regulatory T cells suppressed allograft rejection in ABO-incompatible heart transplantation.

Genes Dis 2022 Jan 28;9(1):1-4. Epub 2021 Jul 28.

Division of Nephrology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.

View Article and Full-Text PDF
January 2022

Tocilizumab in the Treatment of Chronic Antibody-Mediated Rejection Post Kidney Transplantation: Clinical and Histological Monitoring.

Front Med (Lausanne) 2021 24;8:790547. Epub 2021 Dec 24.

Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, University Hospital Grenoble, Grenoble, France.

Chronic antibody-mediated rejection (cAMR) has very few effective therapeutic options. Interleukin-6 is an attractive target because it is involved in inflammation and humoral immunity. Therefore, the use of tocilizumab (anti-IL6 receptor, TCZ) is a potential valuable therapeutic option to treat cABMR in kidney-transplant (KT) recipients. Read More

View Article and Full-Text PDF
December 2021

Complement blockade with eculizumab to treat acute symptomatic humoral rejection after heart transplantation.

Xenotransplantation 2022 Jan 10:e12726. Epub 2022 Jan 10.

Center for Organ Transplantation, Lausanne University Hospital (CHUV) and Lausanne University, Lausanne, Switzerland.

Antibody-mediated rejection (AMR) is a major barrier preventing successful discordant organ xenotransplantation, but it also occurs in allotransplantation due to anti-HLA antibodies. Symptomatic acute AMR is rare after heart allograft but carries a high risk of mortality, especially >1 year after transplant. As complement activation may play a major role in mediating tissue injury in acute AMR, drugs blocking the terminal complement cascade like eculizumab may be useful, particularly since "standards of care" like plasmapheresis are not based on strong evidence. Read More

View Article and Full-Text PDF
January 2022

Pulmonary Pathology of End-Stage COVID-19 Disease in Explanted Lungs and Outcomes After Lung Transplantation.

Am J Clin Pathol 2022 Jan 6. Epub 2022 Jan 6.

Departments of Pathology, NYU Langone Medical Center, New York University School of Medicine, New York, NY, USA.

Objectives: Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may develop end-stage lung disease requiring lung transplantation. We report the clinical course, pulmonary pathology with radiographic correlation, and outcomes after lung transplantation in three patients who developed chronic respiratory failure due to postacute sequelae of SARS-CoV-2 infection.

Methods: A retrospective histologic evaluation of explanted lungs due to coronavirus disease 2019 was performed. Read More

View Article and Full-Text PDF
January 2022

Fungal infections in lung transplantation.

J Thorac Dis 2021 Nov;13(11):6695-6707

University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Lung transplant is a potential life-saving procedure for chronic lung diseases. Lung transplant recipients (LTRs) are at the greatest risk for invasive fungal infections (IFIs) among solid organ transplant (SOT) recipients because the allograft is directly exposed to fungi in the environment, airway and lung host defenses are impaired, and immunosuppressive regimens are particularly intense. IFIs occur within a year of transplant in 3-19% of LTRs, and they are associated with high mortality, prolonged hospital stays, and excess healthcare costs. Read More

View Article and Full-Text PDF
November 2021

Viral infections in lung transplantation.

J Thorac Dis 2021 Nov;13(11):6673-6694

Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland.

Viral infections account for up to 30% of all infectious complications in lung transplant recipients, remaining a significant cause of morbidity and even mortality. Impact of viral infections is not only due to the direct effects of viral replication, but also to immunologically-mediated lung injury that may lead to acute rejection and chronic lung allograft dysfunction. This has particularly been seen in infections caused by herpesviruses and respiratory viruses. Read More

View Article and Full-Text PDF
November 2021

Bacterial infections in lung transplantation.

J Thorac Dis 2021 Nov;13(11):6654-6672

University of Chicago Medicine, Section of Infectious Diseases and Global Health, Chicago, IL, USA.

Lung transplantation has lower survival rates compared to other than other solid organ transplants (SOT) due to higher rates of infection and rejection-related complications, and bacterial infections (BI) are the most frequent infectious complications. Excess morbidity and mortality are not only a direct consequence of these BI, but so are subsequent loss of allograft tolerance, rejection, and chronic lung allograft dysfunction due to bronchiolitis obliterans syndrome (BOS). A wide variety of pathogens can cause infections in lung transplant recipients (LTRs), including a number of nosocomial pathogens and other multidrug-resistant (MDR) pathogens. Read More

View Article and Full-Text PDF
November 2021

Management of chronic rejection after lung transplantation.

J Thorac Dis 2021 Nov;13(11):6645-6653

Division of Pulmonary & Critical Care Medicine, Washington University School of Medicine, MO 63110, USA.

Outcomes after lung transplantation are limited by chronic lung allograft dysfunction (CLAD). The incidence of CLAD is high, and its clinical course tends to be progressive over time, culminating in graft failure and death. Indeed, CLAD is the leading cause of death beyond the first year after lung transplantation. Read More

View Article and Full-Text PDF
November 2021

Impact of G-CSF Therapy on Leukopenia and Acute Rejection Following Kidney Transplantation.

Int J Organ Transplant Med 2021 ;12(2):1-8

Department of General and Digestive Surgery, Section of Transplant Surgery, Medical Center, Faculty of Medicine, University of Freiburg, Germany.

Background: Leukopenia is a common problem after kidney transplantation. The therapeutic approach typically includes a reduction of the immunosuppressive therapy, which is associated with an increased risk of rejection and allograft loss. Granulocyte colony-stimulating factor (G-CSF) is used as a therapeutic option to raise the leukocyte blood count; however, the effect on acute rejections is controversial. Read More

View Article and Full-Text PDF
January 2021